HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by BAKER, L. H. Articles by COLTMAN, C. A. Search for Related Content PubMed PubMed Citation Articles by BAKER, L. H. Articles by COLTMAN, C. A., Jr.

Mitomycin C, Vincristine, and Bleomycin Therapy for Advanced Cervical Cancer

From the Department of Oncology at Wayne State University, Delroit. the Department of Ostuopathic Medicine at Michigan Slate University, East Lansing, Michigan, the Department of Medicine at Ohio Slate University, Columbus, Ohio, the Department of Medicine at the University of Oklahoma, Oklahoma City, Oklahoma, and the Department of Medicine at Wilford Hall USAF Medical Center, Lackland Al-B, Texas

Abstract

The Southwest Oncology Group has treated 130 patients with advanced disseminated uterine cervical carcinoma no longer amenable to therapy with further radiation or surgery. Patients received one of three different schedules of mitomycin C, vincristine and bleomycin. A twice weekly schedule of bleomycin and vincristine produced response in 60% of patients. An infusion bleomycin schedule produced response in 39% of patients and a once weekly vincristine bleomycin schedule produced a 25% response rate (45% overall). Responding patients lived significantly longer than nonresponders (30 vs 18 weeks). Toxicities encountered included leukopenia, thrombocytopenia, peripheral neuropathy, gastrointestinal upset, dermatitis, and alopecia. We believe two of the schedules utilized represent an improvement in producing tumor remission induction in this previously recognized refractory carcinoma.

This article has been cited by other articles:

				F. Pinguet, S. Culine, F. Bressolle, C. Astre, M.-P. Serre, C. Chevillard, and M. Fabbro A Phase I and Pharmacokinetic Study of Melphalan Using a 24-hour Continuous Infusion in Patients with Advanced Malignancies Clin. Cancer Res., January 1, 2000; 6(1): 57 - 63. [Abstract] [Full Text]